Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether Warfarin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients with Hypersplenism after Laparoscopic Splenectomy.
After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. The baseline Doppler parameter will be recorded and the patient will be randomized into either interventional (warfarin) or control (aspirin) group. From postoperative day 3, patients in interventional (warfarin) group will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year, patients in control (aspirin) group will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year, and both groups will be along with five days of subcutaneous injection of Low Molecular Weight Heparin and three months of oral Dipyridamole. Every 3 months the Doppler screening for the occurrence of portal vein thrombus (PVT) or spleno-mesenteric thrombosis will be done for all patients. Both groups will receive the therapy for one year irrespective of the Doppler findings in relation to portal vein thrombus occurrence. Then one year monitoring will be done in the both groups as per the primary or secondary outcome.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Warfarin with dipyridamole | Experimental | From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus. |
|
| Aspirin with dipyridamole | Active Comparator | From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Warfarin | Drug | From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportions of patients who will suffer from PVT or spleno-mesenteric thrombosis between oral anticoagulant Warfarin with dipyridamole group and oral Aspirin with dipyridamole group during the study period of 3 year from randomization | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Proportions of patients who will show improvement in Child Pugh (>2 points)in both groups | 3 years | |
| Proportions of patients who will show improvement in Model for End Stage Liver Disease (MELD)(>4 points)in both groups | 3 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guo-Qing Jiang, MS | Contact | 86-514-87373272 | jgqing2003@hotmail.com | |
| Dou-sheng Bai, MD | Contact | 86-514-87373275 | bdsno1@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Dou-Sheng Bai, MD | Clinical Medical College of Yangzhou University | Study Chair |
| Guo-Qing Jiang, MS | Clinical Medical College of Yangzhou University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Medical College of Yangzhou University | Recruiting | Yangzhou | Jiangsu | 225001 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Dipyridamole | Drug | From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months. |
|
|
| Aspirin | Drug | From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year. |
|
|
| Low Molecular Weight Heparin | Drug | From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days. |
|
|
| Proportions of patients who will show decrease in hepatic decompensation defined as development of ascites, PSE, portal hypertensive bleeding, jaundice, spontaneous bacterial peritonitis, or systemic infection | 3 years |
| Proportions of patients who will suffer from hepatocellular carcinoma | 3 years |
| Overall survival in both groups | 3 years |
| Ping Chen, MD |
| Clinical Medical College of Yangzhou University |
| Principal Investigator |
| Sheng-Jie Jin | Clinical Medical College of Yangzhou University | Principal Investigator |
| ID | Term |
|---|---|
| D005355 | Fibrosis |
| D006973 | Hypertension |
| D020246 | Venous Thrombosis |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
Not provided
Not provided
| ID | Term |
|---|---|
| D014859 | Warfarin |
| D004176 | Dipyridamole |
| D001241 | Aspirin |
| C024079 | aspirin, magnesium oxide combination |
| D006495 | Heparin, Low-Molecular-Weight |
| D017762 | Nadroparin |
| ID | Term |
|---|---|
| D015110 | 4-Hydroxycoumarins |
| D003374 | Coumarins |
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D011743 | Pyrimidines |
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D006493 | Heparin |
| D006025 | Glycosaminoglycans |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
Not provided
Not provided